Donor Lymphocyte Infusion (DLI) as Adoptive Immunotherapy for Relapse Malignancies After Allogeneic Hematopoietic Transplantation
OBJECTIVES: I. Offer donor lymphocyte infusion as adoptive immunotherapy in patients with
relapsed malignancies after allogeneic bone marrow or peripheral blood stem cell
transplantation and who are not eligible for other FHCRC protocols.
OUTLINE: Patients with rapidly progressive disease receive reinduction chemotherapy and
radiotherapy prior to study therapy. Donor lymphocyte infusions (DLI) begin after recovery
from chemotherapy or sooner, if clinically indicated. Patients receive 1 or more DLI from
the original donor. Patients are followed monthly for 3 months, then every 3-6 months for 9
PROJECTED ACCRUAL: An unlimited number of patients will be accrued for this study.
Primary Purpose: Treatment
Mary E. D. Flowers, MD
Fred Hutchinson Cancer Research Center
United States: Federal Government
|Fred Hutchinson Cancer Research Center||Seattle, Washington 98109|